Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 10/20 | 0.41 |
| ▸ | RAB9A | P51151 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468859 | 0.89 | USP2 (0.38) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL3468671 | 0.75 | RAB9A (0.49) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL3468650 | 0.75 | OGA (0.40) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL14403376 | 0.71 | RAB9A (0.65) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL14917116 | 0.71 | AR (0.65) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL1743020 | 0.71 | HDAC4 (0.40) | HRH3 | |
| SCHEMBL9960398 | 0.70 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL3468605 | 0.70 | HPGD (0.69) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL1740888 | 0.70 | NPC1 (0.39) | SMN1; SMN2MAPTTP53NPC1RAB9A | |
| SCHEMBL23269733 | 0.70 | NPC1 (0.70) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | claimed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | claimed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | claimed |
| EP-1999120-B1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | claimed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1999120-B1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | SMN1; SMN2 4655/4885MAPT 1467/4885TP53 4576/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | SMN1; SMN2 4563/4885MAPT 1511/4885TP53 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.